Matt Hewitt
Stock Analyst at Craig-Hallum
(2.67)
# 1,996
Out of 4,883 analysts
40
Total ratings
51.35%
Success rate
3.66%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $17.75 | +102.82% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $7.68 | +56.25% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.56 | +134.38% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $22.84 | +40.11% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $29.84 | +114.48% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $2.09 | +378.47% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $21.12 | +42.05% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $2.24 | +213.20% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $127.47 | +56.90% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $1.93 | +418.13% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $8.29 | +261.88% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.99 | +40,304.04% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $17.75
Upside: +102.82%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $7.68
Upside: +56.25%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.56
Upside: +134.38%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $22.84
Upside: +40.11%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $29.84
Upside: +114.48%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $2.09
Upside: +378.47%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $21.12
Upside: +42.05%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $2.24
Upside: +213.20%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $127.47
Upside: +56.90%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.93
Upside: +418.13%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $8.29
Upside: +261.88%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.99
Upside: +40,304.04%